Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.

Abstract

Human hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Currently, surgical resection is the only effective treatment for HCC if the tumor is resectable. Small molecule, biologics and siRNA anti-cancer drugs have been explored for the treatment of HCC. Selective targeting to tumor tissue rather than normal liver in HCC patients is still a challenge. Galactosamine-mediated targeting delivery of anti-cancer drugs in the liver has been tested because its receptor, asialoglycoprotein receptor 1 (ASGPR1), is expressed in the liver and not in other human tissues. We examined ASGPR1 expression levels by immunohistochemistry in HCC with different grades. Guidance for a targeting delivery strategy for anti-cancer drugs to HCC is suggested in this report.

• Authors: Bin Shi, Marc Abrams, Laura Sepp-Lorenzino
• Journal: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (J Histochem Cytochem) Vol. 61 Issue 12 Pg. 901-9 (Dec 2013) ISSN: 1551-5044 [Electronic] United States
• PMID: 23979840 (Publication Type: Journal Article)

Chemical References

• ASGR1 protein, human
• Asialoglycoprotein Receptor

Topics

• Asialoglycoprotein Receptor (analysis, biosynthesis)
• Carcinoma, Hepatocellular (metabolism, pathology)
• Humans
• Immunohistochemistry
• Liver Neoplasms (metabolism, pathology)